Fairvalue-Calculator Fairvalue-Calculator
EN DE

Wiltrom Co (6767) Fair Value & Analysis

Healthcare · TW · Market cap 999M TWD

Price25.00 TWD
Fair Value43.85 TWD
Upside+75.4%
Quality95/100
Evidence: Low Range 32.89 TWD – 54.81 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Wiltrom Co (6767) currently trades at 25.00 TWD, while our model-based Fair Value estimate is 43.85 TWD — implying the stock looks roughly 75.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Wiltrom Co., Ltd. researches, develops, manufactures, and sells medical equipment in Taiwan. It offers spinal fixation systems, interbody fusion systems, bone graft substitutes, vertebral body augmentation systems, and vertebroplasty bone cement. The company was founded in 1998 and is based in Zhubei, Taiwan.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Wiltrom Co (6767) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 43.85 TWD versus a price of 25.00 TWD — about +75% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6767?
Our 21-model fair value for Wiltrom Co is 43.85 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 25.00 TWD.
What is the quality score of 6767?
Wiltrom Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.